Cardiac Mitochondrial Function After Heart Transplantation (ENERGY-HTX)

August 10, 2020 updated by: University of Aarhus

Studies have shown that cardiac function is affected immediately after heart transplantation (HTx), but seems to recover to some extent over the first year. This immediate effect is associated with lack of oxygen in the tissue and reperfusion injury causing cellular energy depletion, mitochondrial failure and cellular damage. This condition may progress into full blown primary graft failure (PGF), characterized as deterioration of the transplanted heart, which is seen in 3-30 % of HTx patients. In addition to PGF, chronic rejection owing to cardiac allograft vasculopathy (CAV) may develop.

PGF and CAV remain the major heart related mortality causes, and additional assessment and treatments are therefore needed.

Acute cellular rejection (ACR) is diagnosed based on endomyocardial biopsies (EMB), which are routinely performed to ensure prober immunosuppression in HTx patients. ACR occur in approximately 25% of HTx patients, and is associated with PGF and CAV. However, mitochondrial function and integrity may prove to be a more sensitive marker of allograft rejection than endomyocardial biopsies. Therefore, assessment of mitochondrial function may allow for earlier detection of allograft rejection and dysfunction. This may be of particular importance as emerging treatments are targeting both energy substrate supply for adenosine-triphosphate generation produced by the mitochondria and mitochondrial function in the failing heart.

Despite the association between graft rejection and mitochondrial function, it remains unsettled whether mitochondrial function associate with PGF, ACR and CAV. Such findings may be of prognostic importance and even elucidate new treatment targets. Hence, we evaluate the mitochondrial status in HTx patients through four studies designed to assess different aspects of the interplay between cardiac function and mitochondrial integrity and function.

Hypotheses:

Study 1: Primary graft pump function is correlated to mitochondrial function in the first myocardial biopsy taken from the donor heart during the operation.

Study 2: Cardiac mitochondrial function improves over the first 3 months after a heart transplantation.

Study 3: Heart transplant patients with moderate to severe coronary graft vasculopathy has impaired mitochondrial function.

Study 4: Myocardial external energy efficiency by positron-emission tomography can be used as a marker of mitochondrial function and chronic rejection in HTx patients.

Study Overview

Status

Enrolling by invitation

Conditions

Detailed Description

Background

The prognosis after heart transplantation (HTx) has improved considerably since the first HTx was performed in 1967. Studies from our group have shown both left and right ventricular function is affected immediately after heart transplantation, but this seems to recover to some extent over the first year. This immediate effect on the graft organ following HTx is associated with tissue ischemia and reperfusion injury causing cellular energy depletion, mitochondrial failure and subsequent apoptosis. The condition may progress into full blown primary graft failure (PGF) with a need for mechanical cardiovascular support or inotropes which is seen in 3-30 % of HTx patients. The cardiac injury will consequently increase the risk of morbidity as well as mortality. In addition to acute PGF, a chronic rejection owing to coronary arterial vasculopathy (CAV) may develop. Hence, despite advances in peritransplantation treatment and immunosuppression, PGF and CAV remain the major heart related mortality causes following HTx and additional assessment and treatments are therefore needed.

Graft rejection is diagnosed, and the severity graded based on endomyocardial biopsies (EMB) taken percutaneously through the jugular or femoral veins. These biopsies are routinely performed at our institution to ensure prober immunosuppression following HTx.1 Acute cellular rejection (ACR) may occur in approximately 25% of the patients which is associated with PGF, CAV and later chronic rejection. However, mitochondrial function and integrity may prove to be a more sensitive marker of allograft rejection. In heart failure, mitochondria density changes while function and integrity is impaired linking the failing heart to energy deprivation. Animal studies demonstrate that deterioration in total mitochondrial function precedes histopathological changes during cardiac graft rejection following HTx. Therefore, assessment of mitochondrial function following HTx may allow for earlier detection of rejection and allograft dysfunction. This may be of particular importance as emerging treatments are targeting both energy substrate supply for adenosine-triphosphate (ATP) generation produced by the mitochondria as well as mitochondrial function in the failing heart. At our institution, we have established methods to evaluate mitochondrial function in myocardial tissue, and pilot studies have demonstrated feasibility with the use of EMB. In addition, by use of non-invasive 11C-acetate positron-emission tomography (PET), we can assess myocardial external energy efficiency (MEE) calculated by the ratio of myocardial external work (EW) and oxidative metabolism (MVO2). Thus, enabling quantification of coupling between mitochondrial energy production and mechanical work.

Despite the overt association between graft dysfunction/rejection and mitochondrial function, it remains unsettled whether mitochondrial content and function associate with PGF, ACR and CAV. Such findings may be of prognostic importance and even elucidate a new treatment target.

Hypotheses

  1. Primary graft pump function is correlated to mitochondrial function in the first myocardial biopsy taken from the donor heart during the operation
  2. Cardiac mitochondrial function improves over the first 3 months after a heart transplantation
  3. Heart transplant patients with moderate to severe coronary graft vasculopathy has impaired mitochondrial function
  4. MEE can be used as a marker of mitochondrial function and chronic rejection in HTx patients

Objectives

Study 1: To examine whether primary myocardial function is related to cardiac mitochondrial function in de novo HTx patients

Study 2: To investigate whether cardiac mitochondrial function improves over time after HTx along with improvement of cardiac function

Study 3: To examine whether heart transplanted patients with chronic rejection and graft vasculopathy have impaired mitochondrial function

Study 4: To evaluate whether MEE can be used as marker of mitochondrial function and chronic rejection

Design and endpoints

Study 1: The association between cardiac and mitochondrial function following HTx

Design: Myocardial mitochondrial function analyzed from 15 HTx patients taken from the donor heart during the transplantation will be compared to EMB from 15 HTx patients at scheduled biopsies (1 or 2 years after implantation)

Study 2: Development in cardiac and mitochondrial function following HTx Design: Mitochondrial function measured at scheduled EBM follow-up (1,2,3,4,8,12 weeks and 6 months after HTx) from 24 HTx patients. These results are compared to 15 patients with biopsies performed at 1 and 2 years after HTx.

Study 3: The impact of coronary arterial vasculopathy on mitochondrial function Design: Mitochondrial function assessed at scheduled EMB follow-up visits of patients with CAV as determined by coronary angiography (scheduled procedure) 15 HTx patients CAV are compared to 15 HTx patients with without CAV.

Study 4: MEE as a non-invasive marker of mitochondrial function and allograft rejection Design: 24 HTX patients scheduled for EMB will be examined twice with 11C-acetate-PET. It is intended that we consecutively recruit patients enrolled in study 2. The first examination is performed within 3 weeks following HTx and the second examination after 6 months. Up to 4 weeks between EMB and the second 11C-acetate PET examination is accepted.

(The HTx patient cohort which is subjected to biopsies 1 and 2 years after HTx in study 3 (n=15) is reused in study 1 and 2 as a comparable cohort. Hence, a total of 69 patients are enrolled. However, it is anticipated that several patients from study 1 and are enrolled in study 2 which will decrease the total number of participants.)

Methods

Mitochondrial function will be assessed in myocardial biopsies by High-resolution respirometry and Electron microscopy

Cardiac functions is assessed by transthoracic echocardiography

Coronary Angiography is performed to assess the degree of CAV

Blood samples will be taken

In study 4, MEE will be assessed by positron emission tomography using validated kinetic methods.

Ethical considerations

The project will be carried out in accordance with the principles of the Helsinki Declaration II. The protocol, including the written participant information and consent forms must be finally approved by the Research Ethics Committee of the Central Denmark Region and .

Publication and study plan All results, whether positive, negative or inconclusive will be published in an international peer-reviewed scientific journal.

Perspectives Cellular rejection (ACR) shortly after HTx is strongly associated with the long-term development of CAV and subsequent myocardial dysfunction. As graft failure and CAV are the major long-term heart-related late mortality causes following HTx, it seems paramount to modify long-term hazards such as ACR, CAV, and graft failure to significantly improve post-transplant outcome.5 In this context mitochondrial function seems to be pivotal, hence, approaches to assess mitochondrial function in HTx patient may prove to pave the way for new follow-up algorithms and even treatment targets.

Study Type

Observational

Enrollment (Anticipated)

64

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Aarhus, Denmark, 8200 Aarhus
        • Aarhus University Hospital Department of Cardiology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

HTx patients Patients older than 18 years old can be included in this study provided that they give written consent. Pregnant women will not be included in study 4 because of a risk of genetic modifications based on the radiation from the PET-scans.

Description

Inclusion Criteria:

  • Informed consent from participants

Exclusion Criteria:

  • Under 18 years of age
  • Endomyocardial biopsy not feasible assessed by surgeon
  • Pregnancy (Study 4 only)
  • Myocardial infarction, or hospitalization within 1 month due to any cardiac cause (Study 4 only)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
De novo HTx

Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.

Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).

Procedure: is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.

Diagnostic test: Echocardiography and coronary angiography is part of the scheduled standard HTx follow-up visits.
Longterm HTx

Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).

Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.

Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters.
PET-scan de novo HTx

Radiation: Two PET-scans with 11C-acetate tracer will be performed.

Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.

Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).

Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.

Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Study 1+3: Differences in Mitochondrial oxidative capacity
Time Frame: unpaired comparison differences between groups through study completion, an average of 2 years)
Mitochondrial respiratory capacity evaluated with high resolution respirometry,
unpaired comparison differences between groups through study completion, an average of 2 years)
Study 2: Changes in mitochondrial oxidative capacity
Time Frame: unpaired comparison differences between groups (through study completion, an average of 2 years)
Changes in mitochondrial respiratory capacity evaluated with high resolution respirometry,
unpaired comparison differences between groups (through study completion, an average of 2 years)
Study 4: Changes in myocardial external energy efficiency
Time Frame: Changes from baseline (following HTX) to 6-month post-HTX (paired data)

Changes Myocardial external energy efficiency evaluated by PET-scans with 11C-acetate tracer.

Calculated by the ratio of myocardial external work (EW) and oxidative metabolism (MVO2).
Changes from baseline (following HTX) to 6-month post-HTX (paired data)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biochemistry
Time Frame: Through study completion, an average of 2 years.
TNT, proBNP, IL-1, IL-6, TNFalpha, sST2
Through study completion, an average of 2 years.
Cardiac function
Time Frame: Through study completion, an average of 2 years.
Left ventricular function (GLS) assessed by echocardiography
Through study completion, an average of 2 years.
Invasive hemodynamics
Time Frame: Through study completion, an average of 2 years.
Pulmonary (mPAP) and wedge pressures (mPCWP) assessed by right heart catheterization
Through study completion, an average of 2 years.
Cellular function
Time Frame: Through study completion, an average of 2 years.

Rejection state in cardiac tissue (assessed on the international scale for tissue rejection by pathologist):

Grade 0R - No rejection. Grade 1R, mild - Interstitial and/or perivascular infiltrate with up to 1 focus of myocyte damage.

Grade 2R, moderate - Two or more foci of infiltrate with associated myocyte damage.

Grade 3R, severe Diffuse infiltrate with multifocal myocyte damage ± edema, ± hemorrhage ± vasculitis.
Through study completion, an average of 2 years.
Mitochondrial structure
Time Frame: Through study completion, an average of 2 years.
Assessed by electron microscopy (mitochondrial density and matrix folding)
Through study completion, an average of 2 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Aarhus

Collaborators

Novo Nordisk A/S

Investigators

  • Principal Investigator: Hans Eiskjær, Prof., Aarhus University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 25, 2019

Primary Completion (Anticipated)

March 1, 2024

Study Completion (Anticipated)

March 1, 2024

Study Registration Dates

First Submitted

March 12, 2019

First Submitted That Met QC Criteria

September 25, 2019

First Posted (Actual)

September 26, 2019

Study Record Updates

Last Update Posted (Actual)

August 11, 2020

Last Update Submitted That Met QC Criteria

August 10, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1-10-72-367-18

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiac Allograft Vasculopathy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe